The importance of miRNAs and epigenetics in acute lymphoblastic leukemia prognosis. Issue 4 (14th November 2018)

• Record Type: Journal Article
• Authors: Ranjbar, Reza; Karimian, Ansar; Aghaie Fard, Arad; Tourani, Mehdi; Majidinia, Maryam; Jadidi‐Niaragh, Farhad; Yousefi, Bahman
• Is Part Of: Journal of cellular physiology. Volume 234:Issue 4(2019:Apr.)
• Page Start: 3216
• Page End: 3230
• Publication Date: 2018-11-14
• Subjects: epigenetics -- leukemia -- non coding RNA; Physiology -- Periodicals; Cell physiology -- Periodicals; 571.6
• DOI: 10.1002/jcp.26510
• Languages: English
• ISSNs: 0021-9541

Abstract

Abstract : Acute lymphoblastic leukemia (ALL), one of the most common malignant human disorders, originates in different important genetic lesions in T‐cell or B‐cell progenitors. ALL is a malignant lymphoid progenitor with peak prevalence in children (2–5 years). The rate of survival when one is suffering from ALL depends on various agents including the age of the patient, responses to anti‐leukemic therapy, and cell biology. miRNAs and epigenetics are important regulatory factors in the expression of genes. miRNAs are noncoding RNA with inhibitory effectors on specific mRNA. Patterns of DNA methylation are profoundly changed in ALL by epigenetic mechanisms. The deciphering of miRNA and the epigenetic pathogenesis in ALL could revolutionize response to the therapy and outcome, and create an enormous promise for novel approaches to reduce the toxic side‐effects of intensive leukemia. Hence, pathogenetic miRNAs and epigenetics leading to the initiation and the progression of ALL are summarized in this review. Abstract : ALL is by far the most common form of leukemia during childhood and it embraces many adulthood hematological malignancies. The deciphering of miRNAs and the epigenetic pathogenesis in ALL could revolutionize response to the therapy and outcome, and create an enormous promise for novel approaches to reduce the toxic side‐effects of intensive leukemia.